long intergenic non-protein coding RNA 2887Genealiases: []
Q-omics provides the consensus-scored LINC02887 profile across patient tissues and cancer cell-line models. LINC02887 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC02887 is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, LINC02887 RNA expression shows 16,408 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, CHOL, and THYM as cancer lineages where LINC02887 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02887 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02887 survival associations across molecular data types. LINC02887 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02887 RNA expression–survival associations across cancer types. High LINC02887 expression shows unfavorable associations in THCA, but favorable associations in HNSC, PAAD, SKCM, LIHC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC02887 RNA expression.
This table summarizes LINC02887 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02887. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02887 shows higher tumor expression in CHOL, READ and LIHC. The CHOL box plot shows higher LINC02887 RNA expression in tumor versus normal tissue (log2 FC = +0.459, t-test p = .004).
This table shows molecular features associated with LINC02887 in patient tissues and cancer cell lines. In patient samples, LINC02887 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
